SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

ASIT Biotech S.A.. (2/23/18). "Press Release: ASIT Biotech Successfully Completes the Second Tranche of Its Capital Increase, Reaching a Total Amount Raised of €13.9 Million [Not for United States, Australia, Canada, Japan, et al.]". Brussels.

Organisations Organisation ASIT Biotech S.A. (Euronext: ASIT – BE0974289218)
  Organisation 2 NewCap. – Investor Relations & Financial Communications
Products Product gp- ASIT+™ grass pollen rhinitis immunotherapy
  Product 2 investment banking
Index terms Index term ASIT Biotech–SEVERAL: investment, 201802 warrant excercise €2.4m for 626k new shares at €3.83/share
  Index term 2 ASIT Biotech–SEVERAL: investment, 201802 private placement capital increase 2nd tranche €2.1m w 544k new shares at €3.83/share
Persons Person Legon, Thierry (ASIT Biotech 201605 CEO)
  Person 2 Orešanský, Dušan (NewCap 201404)

Record changed: 2018-02-28


Picture [LSUS] – The Business Web Portal 600x60px

More documents for ASIT Biotech S.A. (Euronext: ASIT – BE0974289218)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 600x60px

» top